← The Wire
SNDXNasdaq
Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
red 8-K · 90d
$1.62B
Market cap
$21.78
Last close
+2.2%
1D
+12.7%
5D
4.7M
Volume
Price · last 39 sessions+9.1%
May 4L $16.96 · H $21.78Jun 29
227
Total filings
Jun 10, 2026
Last filing
12/31
Fiscal year end
10-K10-KFeb 26, 202610-K10-KMar 3, 202510-K10-KFeb 27, 202410-K10-KFeb 28, 202310-K10-KMar 1, 202210-K10-KMar 12, 202110-K10-KMar 5, 202010-K10-KMar 7, 201910-K10-KMar 8, 201810-KFORM 10-KMar 14, 2017
Insider Activity
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance